Media headlines about Affymetrix (NASDAQ:AFFX) have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Affymetrix earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media headlines about the scientific and technical instruments company an impact score of 45.5407796716196 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Affymetrix (NASDAQ:AFFX) opened at $14.01 on Wednesday. Affymetrix has a 12 month low of $8.28 and a 12 month high of $16.15.
WARNING: This article was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://sportsperspectives.com/2017/12/20/affymetrix-affx-receives-daily-media-sentiment-rating-of-0-11.html.
Affymetrix, Inc (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry.
Receive News & Ratings for Affymetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymetrix and related companies with MarketBeat.com's FREE daily email newsletter.